Ardelyx 10-Q: Q3 Revenue $127.7M, Net Loss $0.7M, $285.3M Cash, New Securities Suit Disclosed
ARDX is trading near its 52-week low of $2.955 (4.2% above the low).
Summary
Ardelyx's Q3 10-Q confirms $127.7M of revenue and a $0.7M net loss with $285.3M of cash and investments, enough for at least a year of operations, while disclosing a new securities class action and a related derivative suit and closing out the CMS litigation over XPHOZAH reimbursement.
Key Events · Earnings and Guidance · ARDX
-
Q3 Revenue $127.7M, Loss Narrows to $0.7M
Total revenues were $127,655K versus $110,329K a year earlier, with product sales of $125,455K (+19%) split between IBSRELA at $96,286K and XPHOZAH at $29,169K. Net loss was $737K, or $(0.00) per share, versus $969K a year ago.
-
Cash of $285.3M Funds At Least a Year
Cash, cash equivalents and short-term investments totaled $285.3M at September 30, 2026, up from $264.7M at December 31, 2025. Management states this is sufficient to fund planned operations for at least one year from issuance of the financial statements.
-
Debt Rises to $252.4M After Term F Draw
Long-term debt carrying value rose to $252,360K on $250.0M principal after the $50.0M Term F Loan drawn June 29, 2026. The loan matures July 1, 2030 and carries a covenant requiring trailing six-month net product revenue plus unrestricted cash to equal at least 100% of principal outstanding.
-
New Securities Class Action and Derivative Suit
Broadwater v. Ardelyx was filed September 17, 2026 on behalf of purchasers from January 13, 2025 to August 6, 2026, with a lead-plaintiff deadline of November 16, 2026; a related derivative complaint, Marti v. Raab, was filed October 13, 2026. Damages are unspecified and the company says it cannot estimate a range of loss.
Analysis · ARDX · Life Sciences
The quarter was already public via the same-day 8-K, but the 10-Q is where the balance sheet and legal picture land. At September 30, 2026, Ardelyx held $285.3M in cash and investments, up from $264.7M at year-end, and management states that is enough to fund planned operations for at least a year — so there is no near-term financing need despite the stock sitting near its 52-week low. Offsetting that, long-term debt carrying value rose to $252.4M after the $50.0M Term F draw in June, and the loan carries a covenant requiring trailing six-month net product revenue plus unrestricted cash to cover 100% of principal outstanding. The filing also puts two new legal matters on the record: a securities class action filed September 17, 2026 covering purchasers from January 13, 2025 through August 6, 2026 (the day of the guidance cut), with a lead-plaintiff deadline of November 16, 2026, and a related derivative suit filed October 13, 2026. Both are unquantified, but they keep litigation risk live over the guidance revision. On the positive side, the CMS lawsuit over XPHOZAH's ESRD PPS placement is finally over — the D.C. Circuit affirmed dismissal on June 26, 2026 and the company is not appealing further — and the ACCEL Phase 3 CIC trial is fully enrolled with topline data expected in the second half of 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARDX was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $755M. The 52-week trading range was $2.96 to $8.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.